Lilly urges degrader caution
Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.
Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.
Golcadomide will begin a new pivotal trial in follicular lymphoma.
The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.
The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.
In first-line breast cancer vepdegestrant will be combined with Pfizer’s investigational CDK4 inhibitor atirmociclib.
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.